Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease

TY - JOUR

T1 - Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease

AU - D'Haens, Geert

AU - Rieder, Florian

AU - Feagan, Brian G.

AU - Higgins, Peter D. R.

AU - Panés, Julian

AU - Maaser, Christian

AU - Rogler, Gerhard

AU - Löwenberg, Mark

AU - van der Voort, Robbert

AU - Pinzani, Massimo

AU - Peyrin-Biroulet, Laurent

AU - Danese, Silvio

AU - International Organization for Inflammatory Bowel Disease Fibrosis Working Group

AU - Allocca, Mariangela

AU - de Hertogh, Gert

AU - Denton, Chris

AU - Distler, J. rg

AU - McCarrier, Kelly

AU - McGovern, Dermot

AU - Radstake, Tim

AU - Serrano, Daniel

AU - Stoker, Jaap

N1 - Funding Information: Funding This meeting was supported through unrestricted grants from Celgene, Gilead, GlaxoSmithKline, Pfizer, Roche, and Union Chimique Belge (UCB) Pharma. Funding Information: Conflicts of interest These authors disclose the following: Geert D’Haens has served as advisor for Abbvie, Ablynx, Allergan, Alphabiomics, Amakem, Amgen, AM Pharma, Arena Pharmaceuticals, AstraZeneca, Avaxia, Biogen, Bristol Meiers Squibb, Boehringer Ingelheim, Celgene/Receptos, Celltrion, Cosmo, Echo Pharmaceuticals, Eli Lilly, Engene, Ferring, DrFALK Pharma, Galapagos, Genentech/Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Hospira/Pfizer, Immunic, Johnson & Johnson, Kintai Therapeutics, Lycera, Medimetrics, Millenium/Takeda, Medtronics, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Nextbiotics, Novonordisk, Otsuka, Pfizer/Hospira, Photopill, Prodigest, Prometheus Laboratories/Nestle, Progenity, Protagonist, RedHill, Robarts Clinical Trials, Salix, Samsung Bioepis, Sandoz, Seres/Nestle, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant, and Vifor; and received speaker fees from Abbvie, Biogen, Ferring, Johnson & Johnson, Merck Sharp Dome, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Millenium/Takeda, Tillotts, and Vifor. Florian Rieder received consulting fees from Allergan, AbbVie, Boehringer Ingelheim, Celgene, Cowen, Gilead, Gossamer, Helmsley, Janssen, Koutif, Metacrine, Pliant, Pfizer, Receptos, RedX, Roche, Samsung, Takeda, Thetis, and UCB; and research funding from Boehringer Ingelheim, UCB, Celgene, and Pliant. Brian Feagan received grants and/or research support from AbbVie Inc, Amgen Inc, AstraZeneca/MedImmune Ltd, Atlantic Pharmaceuticals Ltd, Boehringer-Ingelheim, Celgene Corporation, Celltech, Genentech Inc/Hoffmann-La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline, Janssen Research & Development LLC, Pfizer Inc, Receptos Inc/Celgene International, Sanofi, Santarus Inc, Takeda Development Center Americas Inc, Tillotts Pharma AG, and UCB; is a consultant for Abbott/AbbVie, Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc, Aptevo Therapeutics, Astra Zeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer-Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, Galen/Atlantica, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, Intact Therapeutics, JnJ/Janssen, Kyowa Kakko Kirin Co Ltd, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestles, Nextbiotix, Novonordisk, ParImmune, Parvus Therapeutics Inc, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Qu Biologics, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc, Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd, and Zyngenia; is affiliated with the speakers bureau of Abbott/AbbVie, JnJ/Janssen, Lilly, Takeda, Tillotts, UCB Pharma; is a member of the scientific advisory board of Abbott/AbbVie, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc, Elan/Biogen, Galapagos, Genentech/Roche, JnJ/Janssen, Merck, Nestles, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG, and UCB Pharma; and is a Senior Scientific Officer of Robarts Clinical Trials Inc (London). Peter Higgins has served as a consultant for Abbvie, Genentech, UCB, and Takeda, and has received educational grants and research grants from Abbvie, Janssen, Pfizer, and Takeda. Julian Panés received consulting fees from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Ferring, Genentech, GlaxoSmithKline, Janssen, MSD, Nestle, Oppilan, Pfizer, Progenity, Robarts, Roche, Takeda, Theravance, and TiGenix; speaker fees from AbbVie, Janssen, MSD, and Takeda; and research funding from AbbVie and MSD. Christian Maaser has served as a speaker, consultant and/or advisory board member for Abbvie, Celgene, Falk Foundation, Ferring, Janssen, MSD, Pfizer, Takeda, and Vifor. Gerhard Rogler has consulted to Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; received speaker's honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor, and Zeller; and educational grants and research grants from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB, and Zeller. Mark Löwenberg has served as speaker, consultant, or principal investigator for Abbvie, Celgene, Covidien, Dr Falk, Ferring Pharmaceuticals, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts, and Tramedico; and received research grants from AbbVie, Merck Sharp & Dohme, Achmea Healthcare, Dr Falk, and ZonMW. Massimo Pinzani is an inventor and patent holder (ELF test) for Siemens; and served as a speaker or consultant for Echosens, Promethera, Neurovive, Chemomab, Median Technology, UCB Cell Tech, Boehringer Ingelheim, Engitix Ltd, 3P-Sense Ltd, and Hepatotargets. Laurent Peyrin-Biroulet has served as a speaker for Merck, Abbvie, Janssen, Genentech, Ferring, Tillots, Vifor, Pharmacosmos, Celltrion, Takeda, Boerhinger-Ingelheim, Pfizer, Amgen, Biogen, and Samsung Bioepis; and as a consultant for Merck, Abbvie, Janssen, Genentech, Ferring, Tillots, Vifor, Pharmacosmos, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, Pfizer, Index Pharmaceuticals, Amgen, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestlé, Enterome, Mylan, and HAC-Pharma. Silvio Danese has served as a speaker, a consultant, and an advisory board member for Abbvie, Allergan, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer, Sandoz, Tigenix, UCB Pharma, and Vifor. The remaining author discloses no conflicts. Funding Information: International Organization for Inflammatory Bowel Disease Fibrosis Working Group, Mariangela Allocca, IBD Center, Humanitas Clinical and Research Hospital, Humanitas University, Milan, Italy; Gert De Hertogh, University Hospitals Leuven, Department of Pathology, Leuven, Belgium; Chris Denton, Royal Free Hospital, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, UK; J?rg Distler, Friedrich-Alexander-University, Erlangen-N?rnberg and Universit?tsklinikum Erlangen, Department of Internal Medicine 3, Rheumatology and Immunology, Erlangen, Germany; Kelly McCarrier, Pharmerit, Bethesda, Maryland; Dermot McGovern, Cedars-Sinai Medical Center, Medical Genetics Research Institute, Department of Medicine, Los Angeles, California; Tim Radstake, University Medical Center Utrecht, Utrecht University, Laboratory of Translational Immunology, and Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands; Daniel Serrano, Pharmerit, Bethesda, Maryland; and Jaap Stoker, Cancer Center Amsterdam, Amsterdam University Medical Center, Academic Medical Center, Departments of Radiology and Nuclear Medicine, Amsterdam, The Netherlands. Conflicts of interest These authors disclose the following: Geert D'Haens has served as advisor for Abbvie, Ablynx, Allergan, Alphabiomics, Amakem, Amgen, AM Pharma, Arena Pharmaceuticals, AstraZeneca, Avaxia, Biogen, Bristol Meiers Squibb, Boehringer Ingelheim, Celgene/Receptos, Celltrion, Cosmo, Echo Pharmaceuticals, Eli Lilly, Engene, Ferring, DrFALK Pharma, Galapagos, Genentech/Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Hospira/Pfizer, Immunic, Johnson & Johnson, Kintai Therapeutics, Lycera, Medimetrics, Millenium/Takeda, Medtronics, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Nextbiotics, Novonordisk, Otsuka, Pfizer/Hospira, Photopill, Prodigest, Prometheus Laboratories/Nestle, Progenity, Protagonist, RedHill, Robarts Clinical Trials, Salix, Samsung Bioepis, Sandoz, Seres/Nestle, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant, and Vifor; and received speaker fees from Abbvie, Biogen, Ferring, Johnson & Johnson, Merck Sharp Dome, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Millenium/Takeda, Tillotts, and Vifor. Florian Rieder received consulting fees from Allergan, AbbVie, Boehringer Ingelheim, Celgene, Cowen, Gilead, Gossamer, Helmsley, Janssen, Koutif, Metacrine, Pliant, Pfizer, Receptos, RedX, Roche, Samsung, Takeda, Thetis, and UCB; and research funding from Boehringer Ingelheim, UCB, Celgene, and Pliant. Brian Feagan received grants and/or research support from AbbVie Inc, Amgen Inc, AstraZeneca/MedImmune Ltd, Atlantic Pharmaceuticals Ltd, Boehringer-Ingelheim, Celgene Corporation, Celltech, Genentech Inc/Hoffmann-La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline, Janssen Research & Development LLC, Pfizer Inc, Receptos Inc/Celgene International, Sanofi, Santarus Inc, Takeda Development Center Americas Inc, Tillotts Pharma AG, and UCB; is a consultant for Abbott/AbbVie, Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc, Aptevo Therapeutics, Astra Zeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer-Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, Galen/Atlantica, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, Intact Therapeutics, JnJ/Janssen, Kyowa Kakko Kirin Co Ltd, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestles, Nextbiotix, Novonordisk, ParImmune, Parvus Therapeutics Inc, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Qu Biologics, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc, Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd, and Zyngenia; is affiliated with the speakers bureau of Abbott/AbbVie, JnJ/Janssen, Lilly, Takeda, Tillotts, UCB Pharma; is a member of the scientific advisory board of Abbott/AbbVie, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc, Elan/Biogen, Galapagos, Genentech/Roche, JnJ/Janssen, Merck, Nestles, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG, and UCB Pharma; and is a Senior Scientific Officer of Robarts Clinical Trials Inc (London). Peter Higgins has served as a consultant for Abbvie, Genentech, UCB, and Takeda, and has received educational grants and research grants from Abbvie, Janssen, Pfizer, and Takeda. Julian Pan?s received consulting fees from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Ferring, Genentech, GlaxoSmithKline, Janssen, MSD, Nestle, Oppilan, Pfizer, Progenity, Robarts, Roche, Takeda, Theravance, and TiGenix; speaker fees from AbbVie, Janssen, MSD, and Takeda; and research funding from AbbVie and MSD. Christian Maaser has served as a speaker, consultant and/or advisory board member for Abbvie, Celgene, Falk Foundation, Ferring, Janssen, MSD, Pfizer, Takeda, and Vifor. Gerhard Rogler has consulted to Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; received speaker's honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor, and Zeller; and educational grants and research grants from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB, and Zeller. Mark L?wenberg has served as speaker, consultant, or principal investigator for Abbvie, Celgene, Covidien, Dr Falk, Ferring Pharmaceuticals, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts, and Tramedico; and received research grants from AbbVie, Merck Sharp & Dohme, Achmea Healthcare, Dr Falk, and ZonMW. Massimo Pinzani is an inventor and patent holder (ELF test) for Siemens; and served as a speaker or consultant for Echosens, Promethera, Neurovive, Chemomab, Median Technology, UCB Cell Tech, Boehringer Ingelheim, Engitix Ltd, 3P-Sense Ltd, and Hepatotargets. Laurent Peyrin-Biroulet has served as a speaker for Merck, Abbvie, Janssen, Genentech, Ferring, Tillots, Vifor, Pharmacosmos, Celltrion, Takeda, Boerhinger-Ingelheim, Pfizer, Amgen, Biogen, and Samsung Bioepis; and as a consultant for Merck, Abbvie, Janssen, Genentech, Ferring, Tillots, Vifor, Pharmacosmos, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, Pfizer, Index Pharmaceuticals, Amgen, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestl?, Enterome, Mylan, and HAC-Pharma. Silvio Danese has served as a speaker, a consultant, and an advisory board member for Abbvie, Allergan, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer, Sandoz, Tigenix, UCB Pharma, and Vifor. The remaining author discloses no conflicts. Funding This meeting was supported through unrestricted grants from Celgene, Gilead, GlaxoSmithKline, Pfizer, Roche, and Union Chimique Belge (UCB) Pharma.

PY - 2022/1/1

Y1 - 2022/1/1

UR - https://www.scopus.com/pages/publications/85120948639

U2 - 10.1053/j.gastro.2019.05.072

DO - 10.1053/j.gastro.2019.05.072

M3 - Article

C2 - 31254502

SN - 0016-5085

VL - 162

SP - 26

EP - 31

JO - Gastroenterology

JF - Gastroenterology

IS - 1

ER -